Table 1 Characteristics of new onset-MG patients and controls
From: Targeting NF-kappaB-inducing kinase shapes B-cell homeostasis in myasthenia gravis
Characteristics | PBMC for FCM detection | Serum for ELISA detection | ||||
|---|---|---|---|---|---|---|
Controls (n = 32) | New-onset MG(n = 45) | P | Controls (n = 50) | New-onset MG(n = 76) | P | |
Age, years | 57.5(51.00,63.75) | 63(48.50,72.00) | 0.227 | 53.00(46.50, 57.25) | 55.00(41.25, 65.00) | 0.419 |
Sex, n(%) | Â | Â | 0.363 | Â | Â | 0.207 |
 Female | 19(59.38) | 22(48.89) |  | 32(64.00) | 40(52.63) |  |
 Male | 13(40.63) | 23(51.11) |  | 18(36.00) | 36(47.37) |  |
Age of onset, n(%) | Â | Â | Â | Â | Â | Â |
 EOMG (age < 50 y) |  | 15(33.33) |  |  | 30(39.47) |  |
 LOMG (age ≥ 50 y) |  | 30(66.67) |  |  | 46(60.53) |  |
Type, n(%) | Â | Â | Â | Â | Â | Â |
 OMG |  | 20(44.44) |  |  | 26(34.21) |  |
 GMG |  | 25(55.56) |  |  | 50(65.79) |  |
MGFA at admission, n(%) | Â | Â | Â | Â | Â | Â |
 I |  | 20(44.44) |  |  | 26(34.21) |  |
 II |  | 10(22.22) |  |  | 17(22.37) |  |
 III |  | 11(24.44) |  |  | 20(26.32) |  |
 IV |  | 4(8.89) |  |  | 13(17.11) |  |
Thymoma, n(%) | Â | Â | Â | Â | Â | Â |
 Without |  | 34(75.56) |  |  | 52(68.42) |  |
 With |  | 11(24.44) |  |  | 24(31.58) |  |
AchR-Ab, n(%) | Â | Â | Â | Â | Â | Â |
 Positive, n(%) |  | 45(100.00) |  |  | 76(100.00) |  |
 Negative, n(%) |  | 0(0.00) |  |  |  |  |